scientific name for retatrutide GLP-1 receptor - Cagrilintide semaglutide GLP-1 receptor Unraveling the Scientific Name for Retatrutide: A Deep Dive into Eli Lilly's Triple Agonist

Retatrutidesynthesis The pharmaceutical landscape is continuously evolving, with groundbreaking research leading to innovative treatments for complex health conditions. Among these advancements, retatrutide has emerged as a significant development, particularly in the realm of obesity and metabolic disorders. While often referred to by its developmental code LY3437943, understanding its scientific nomenclature provides crucial insights into its composition and function. The exact scientific name for retatrutide is directly linked to its complex chemical structure and its role as a peptide.

Delving into the specifics, retatrutide (sodium salt) has a chemical formula of C221H342N46O68. This extensive formula points to its nature as a large molecule, specifically a peptide. The exact mass of this compound is 4728.4718, with a molecular weight of 4731.34. This detailed molecular information, available through databases like PubChem and KEGG DRUG, underscores the precision involved in synthesizing such therapeutic agents. The compound is also identified by its DrugBank Accession Number DB18993 and as Retatrutide (USAN).

Retatrutide is recognized for its groundbreaking mechanism of action. It functions as a potent triple hormone receptor agonist.Compound Sciences sells 20 mg of retatrutide (branded asGLP3 RT-20) for .99. This means it simultaneously targets and activates three crucial hormone pathways: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors (GCGR). This triple action is fundamental to its efficacy in addressing weight management and metabolic healthPeople Are Already Taking This Unapproved New Weight- .... The GLP-1 receptor and GIP receptor (GIPR) are key players in regulating appetite, glucose metabolism, and insulin secretion. By activating these, along with the glucagon receptor, retatrutide offers a comprehensive approachThe purpose of this study is to is to evaluate the efficacy and safety ofretatrutidein participants with type 2 diabetes in participants who have obesity ....

The development of retatrutide is spearheaded by the American pharmaceutical giant, Eli Lilly and Company. This well-established entity has a proven track record in bringing innovative treatments to market. The compound was initially known as LY3437943 during its research and development phases. The purity of synthesized retatrutide peptides is remarkably high, often reaching 99KEGG DRUG: Retatrutide.4% or 99.5%, as indicated by research chemical suppliers. For instance, GLP3 RT-20 is a designation for retatrutide available for scientific research, highlighting its application in laboratory settingsEfficacy of Tirzepatide, Retatrutide, and Semaglutide for ....

Clinical trials are actively investigating the efficacy and safety of retatrutide. Studies, such as those registered under NCT05929066 and NCT05929079, are evaluating its impact on individuals with obesity or overweight conditions, and in some cases, those with type 2 diabetesThe power of three: Retatrutide's role in modern obesity .... The ultimate goal is to establish its role in future obesity care, potentially offering a new class of pharmacotherapy.Retatrutide: What is it and is it FDA approved? The research findings have been promising, with studies indicating significant weight loss results, leading to its informal moniker, "the triple G," due to its targeting of three hormonal pathways.

While retatrutide is not yet FDA approved for general use, its potential is generating considerable interest.Retatrutide UK: What it is, benefits & availability Comparisons with other compounds, such as tirzepatide (a dual GIP and GLP-1 receptor agonist) and semaglutide, are frequently madeTriple–Hormone-Receptor Agonist Retatrutide for Obesity. Tirzepatide, known by brand names like Zepbound and Mounjaro, represents a significant advancement, but retatrutide's triple agonism suggests a potentially more potent effectRetatrutide: What is it and is it FDA approved?. The comparison between cagrilintide and semaglutide also exists within the broader context of GLP-1 receptor agonists, further illustrating the evolving therapeutic landscape.

The nomenclature surrounding retatrutide also includes informal names that have emerged in public discourse and the underground market. "GLP-3" is one such term used to refer to retatrutide, particularly in contexts where it might be acquired outside of official clinical trials or regulatory approval.Umbrella Labs Launches Retatrutide (LY3437943) for ... This often applies to research-grade peptides sold by companies like Compound Sciences or Umbrella Labs. For example, Compound Sciences offers 20 mg of retatrutide for $79.99 under the branded name GLP3 RT-20I Bought 'GLP-3'. It is crucial to note that the acquisition and use of such compounds outside of sanctioned research or clinical settings carry inherent risks and are generally not recommended.2024年6月28日—Identification ; Generic Name:Retatrutide; DrugBank Accession Number: DB18993 ; Background. Retatrutide is under investigation in clinical trial ... The CAS number associated with retatrutide is 2381089-83-2.

In summary, the scientific name for retatrutide is intrinsically tied to its precise chemical composition and its function as a triple hormone receptor agonist. Developed by Eli Lilly and Company and identified by codes like LY3437943, this peptide targets GLP-1, GIP, and glucagon receptors. While not yet approved by regulatory bodies, its ongoing clinical evaluation and promising results position it as a significant contender in the future of obesity and metabolic disorder treatment. Understanding its formula (C221H342N46O68), molecular weight, and mechanism of action is essential for researchers, healthcare professionals, and anyone seeking a deeper comprehension of this innovative therapeutic agent.